Proposal of a familial hypercholesterolemia paediatric diagnostic score (FH-PeDS) - Takeaways - MDSpire

Proposal of a familial hypercholesterolemia paediatric diagnostic score (FH-PeDS)

  • By

  • Jan Kafol

  • Beatriz Miranda

  • Rok Sikonja

  • Jaka Sikonja

  • Albert Wiegman

  • Ana Margarida Medeiros

  • Ana Catarina Alves

  • Tomas Freiberger

  • Barbara A Hutten

  • Matej Mlinaric

  • Tadej Battelino

  • FH-PeDS Collaborators

  • Steve E Humphries

  • Mafalda Bourbon

  • Urh Groselj

  • June 20, 2025

  • 0 min

Share

  • 1

    Familial hypercholesterolemia (FH) is underdiagnosed in children, with only 2.1% of adults identified during childhood despite the benefits of early intervention.

  • 2

    The study developed two new diagnostic tools, FH-PeDS and ML-FH-PeDS, which outperform existing criteria in detecting FH in pediatric populations.

  • 3

    Only 47.4% of genetically confirmed FH cases were identified by established diagnostic criteria, highlighting their limitations in children.

  • 4

    ML-FH-PeDS demonstrated superior predictive power with an AUC of 0.932 in training and 0.904 in testing, compared to 0.852 for DLCN.

  • 5

    These tools aim to improve early FH detection and guide genetic testing decisions, potentially reducing long-term cardiovascular risks.

Original Source(s)

Proposal of a familial hypercholesterolemia paediatric diagnostic score (FH-PeDS)

  • by Jan Kafol, Beatriz Miranda, Rok Sikonja, Jaka Sikonja, Albert Wiegman, Ana Margarida Medeiros, Ana Catarina Alves, Tomas Freiberger, Barbara A Hutten, Matej Mlinaric, Tadej Battelino, FH-PeDS Collaborators, Steve E Humphries, Mafalda Bourbon, Urh Groselj

  • June 20, 2025

Related Content

Medical Oddities: Can a Home Be Preventive Care?

This week’s medical plot twists involved ants, architecture, and auditory hallucinations.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.